June 11, 2026 Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
June 11, 2026 As Global Markets Surge to Record Highs, Investors Continue Discovering Elektros Inc.’s Expanding Vision in Lithium, Critical Minerals, and EV Innovation
